[1]王　琪,魏　俊,李小琴.尤瑞克林注射液治疗急性脑梗死的疗效及安全性[J].新乡医学院学报,2016,33(11):980-982.[doi:10.7683/xxyxyxb.2016.11.012]
　WANG Qi,WEI Jun,LI Xiao-qin.Effect and safety of urinary kallidinogenase injection in the treatment of acute cerebral infarction[J].Journal of Xinxiang Medical University,2016,33(11):980-982.[doi:10.7683/xxyxyxb.2016.11.012]
点击复制

尤瑞克林注射液治疗急性脑梗死的疗效及安全性
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
33
期数:
2016年11
页码:
980-982
栏目:
临床研究
出版日期:
2016-11-05

文章信息/Info

Title:
Effect and safety of urinary kallidinogenase injection in the treatment of acute cerebral infarction
作者:
王　琪; 魏　俊; 李小琴
（宜宾市第一人民医院神经内科，四川　宜宾　644000）
Author(s):
WANG Qi; WEI Jun; LI Xiao-qin
(Department of Neurology,the First People′s Hospital of Yibin City,Yibin 644000,Sichuan Province,China)
关键词:
尤瑞克林; 脑梗死; 安全性; 不良反应
Keywords:
urinary kallidinogenase; cerebral infarction; safety; adverse reaction
分类号:
R743.3
DOI:
10.7683/xxyxyxb.2016.11.012
文献标志码:
A
摘要:
目的　观察尤瑞克林注射液治疗急性脑梗死（ACI）的疗效及安全性。方法　选取2013年1月至2015年1月宜宾市第一人民医院收治的ACI患者110例，根据治疗方法分为观察组和对照组，每组55例。对照组患者给予降血脂、控制血压、控制血糖、抗血小板、营养神经、改善脑血液循环、吸氧等常规治疗，观察组患者在常规治疗基础上给予尤瑞克林治疗，比较2组患者的治疗效果，并观察尤瑞克林注射液的用药安全性。结果　治疗前2组患者国立卫生研究院卒中量表（NIHSS）、Barthel指数量表(BI)评分比较差异无统计学意义（P>0.05）。治疗结束后2周，2组患者NIHSS评分显著低于治疗前（P<0.05），BI评分显著高于治疗前（P<0.05）。治疗结束后3个月，2组患者BI评分显著高于治疗前和治疗结束后2周（P<0.05）。2组患者治疗结束后2周椎基底动脉收缩峰期血流速度均显著高于治疗前和治疗结束时（P<0.05）；观察组显著高于对照组（P<0.05）。观察组患者治疗过程中未发现与尤瑞克林明显有关的不良反应。结论　尤瑞克林注射液能够有效改善ACI患者的神经功能，提高生活质量，且安全性较好。
Abstract:
Objective　To observe the effect and safety of urinary kallidinogenase injection in the treatment of acute cerebral infarction(ACI).Methods　A total of 110 patients with ACI were selected in the First People′s Hospital of Yibin City from January 2013 to January 2015.The patients were divided into observation group and control group according to therapeutic method,55 cases in each group.The patients in control group were treated with conventional therapy such as lowering blood fat,controlling blood pressure and blood glucose,antiplatelet,trophic nerve,improving cerebral blood circulation,oxygen inhalation and so on.The patients in observation group were treated with urinary kallidinogenase on the basis of conventional treatment.The effect was compared between the two groups,and the safety of urinary kallidinogenase was observed.Results　There was no significant difference in the national institute of health stroke scale(NIHSS) and Barthel index(BI) score between the two groups before treatment(P>0.05).Two weeks after treatment,the NIHSS score was significantly lower than that before treatment(P<0.05),and the BI score was significantly higher than that before treatment in the two groups (P<0.05).Three months after treatment,the BI score was significantly higher than that before treatment and two weeks after treatment in the two groups(P<0.05).Two weeks after treatment,the peak blood flow velocity of vertebral basilar artery was significantly higher than that before treatment and at the end of treatment in the two groups(P<0.05),and the peak blood flow velocity of vertebral basilar artery in observation group was significantly higher than that in control group(P<0.05).There was no significant urinary kallidinogenase related adverse reaction during the treatment in observation group.Conclusion　Urinary kallidinogenase injection can effectively improve the neurological function,improve the quality of life of ACI patients,and the safety is better.

参考文献/References:

［1］　LING L,HOU Q,XING S,et al.Exogenous kallikrein enhances neurogenesis and angiogenesis in the subventricular zone and the peri-infarction region and improves neurological function after focal cortical infarction in hypertensive rats［J］.Brain Res,2008,1206:89-97.
［2］　XIA C F,YIN H,YAO Y Y,et al.Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis［J］.Hum Gene Ther,2006,17(2):206-219.
［3］　CHEN Z B,HUANG D Q,NIU F N,et al.Human urinary kallidinogenase suppresses cerebral inflammation in experimental stroke and downregulates nuclear factor-kappaB［J］.J Cereb Blood Flow Metab,2010,30(7):1356-1365.
［4］　UENO M,ONODERA M,NAYA T,et al.Axonal damage in acute cerebral infarction showing ADC reduction［J］.J Neurol,2010,257(9):1559-1561.
［5］　王玥，尤如芹，王璐，等.人尿激肽酶原对急性脑梗死患者神经功能及MMP 表达的影响［J］.中国实验诊断学，2015，19（3）：454-456.
［6］　褚雪菲，刘道龙，周军怀，等.大剂量疏血通注射液治疗老年急性脑梗死患者102例［J］.中国老年学杂志，2015，35（12）：3418-3419.
［7］　罗焱，姚平波，张平，等.急性脑梗死患者外周血微小RNA-155和CD4+CD25+Treg细胞表达的关系［J］.实用医学杂志，2015，31（11）：1771-1774.
［8］　王以翠，常焕显，孔令胜.阿加曲班对急性脑梗死患者血管内皮功能及炎症因子的影响［J］.中山大学学报（医学科学版），2015，36（6）：870-876.
［9］　程冉冉，李焰，周燕，等.丁苯酞联合依达拉奉对急性脑梗死患者血清SOD、MDA的影响［J］.中国老年学杂志，2014，34（11）：2974-2975.
［10］　孙肇瑜，徐静，黄敏.尤瑞克林治疗急性脑梗死的护理体会［J］.贵州医药，2013，37（10）：953-954.
［11］　钟长扬，梁丽贞，沈永惠，等.血清缺血修饰蛋白对急性脑梗死诊断价值的研究［J］.中华急诊医学杂志，2014，23（7）：816-817.
［12］　白永杰，刘诗翔.高压氧对急性脑梗死作用机制研究进展［J］.西南国防医药，2014，24（12）：1394-1396.
［13］　LI J S,ZHANG W,KANG Z M,et al.Hyperbaric oxygen preconditioning reduces ischemia-reperfusion injury by inhibition of apoptosis via mitochondrial pathway in rat brain［J］.Neuroscience,2009,159(4):1309-1315.
［14］　EMANUELI C,MADEDDU P.Angiogenesis therapy with human tissue kallikrein for the treatment of ischemic diseases［J］.Arch Mal Coeur Vaiss,2004,97(6):679-687.

相似文献/References:

[1]王泰安.复方丹参联用纳络酮治疗急性脑梗死31例[J].新乡医学院学报,2001,18(04):278.
[2]陈 娟,吕文国.黄芪注射液联合复方丹参注射液治疗急性脑梗死30例[J].新乡医学院学报,2002,19(02):083.
[3]李素芳,王艳.降纤酶联用低分子肝素治疗脑梗死疗效观察[J].新乡医学院学报,2002,19(06):502.
[4]刘世峰,刘江峰.降纤酶与东菱克栓酶治疗急性脑梗死的临床对照观察[J].新乡医学院学报,2002,19(04):291.
[5]张思莲.脑梗死患者患侧股骨颈骨折术后护理[J].新乡医学院学报,2002,19(05):441.
[6]汪裕荣.灯盏花注射液治疗急性脑梗死128例[J].新乡医学院学报,2002,19(01):050.
[7]丁泽昌,吕荣亚.降纤酶治疗脑梗死40例临床疗效观察[J].新乡医学院学报,2003,20(06):438.
[8]崔光琴,王凯。.脑梗死70例急性期血压变化[J].新乡医学院学报,2003,20(06):447.
[9]张晨光,沈琪琳,马振武,等.急性脑梗死患者血液流变学及血细胞参数的变化[J].新乡医学院学报,2003,20(03):177.
[10]周俐红,陈 娟.老年脑梗死合并感染30例分析[J].新乡医学院学报,2003,20(03):210.

更新日期/Last Update: 2016-11-05